

## Commercial/Healthcare Exchange Step Criteria Effective: September 2010

## Step Therapy Name: ACE-ARB Inhibitors

*<u>Step 1 Agent(s)</u>: benazepril/HCT, captopril/HCT, enalapril/HCT, fosinopril/HCT, lisinopril/HCT, quinapril/HCT, ramipril, trandolapril, losartan/HCT, irbesartan/HCT,* 

<u>Step 2 Agent(s)\*</u>: Edarbi, Edarbyclor, Tekturna, Tekturna HCT, telmisartan/HCT, telmisartan/amlodipine, candesartan/HCT, eprosartan, candesartan, olmesartan, olmesartan/HCT, amlodipine/olmesartan, aliskiren, amlodipine/valsartan, telmisartan, valsartan oral solution

## \*Must try TWO (2) Step 1 Agents

## Medication/Class Description:

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.

## **Required Medical Information:**

- 1. Diagnosis
- 2. Previous therapies tried/failed
- 3. Current blood pressure reading

## Age Restrictions:

- 1. <u>Tekturna, olmesartan, aliskiren, valsartan oral solution:</u> 6 years of age and older
- 2. <u>Edarbi, Edarbyclor, telmisartan/HCT, telmisartan/amlodipine, telmisartan, Tekturna HCT, candesartan/HCT, eprosartan, olmesartan/HCT, amlodipine/olmesartan, amlodipine/valsartan</u>: 18 years of age and older
- 3. <u>Candesartan</u>: 1 years of age to < 17 years of age

## Prescriber Restrictions: None

## Coverage Duration: 12 Months

## **Exceptions for Stepped Medications:**

- A. Patient has had a trial and failure of TWO Step 1 Agents, defined as
  - a. Failure to decrease/control blood pressure; OR
- B. Patient has an intolerance or contraindication to TWO Step 1 Agents, defined as (but not limited to):
  - a. Allergic reaction; OR
  - b. Adverse drug reactions.

Last Rev. June 2022



# ConnectiCare

References:

- 1. EDARBYCLOR oral tablets, azilsartan medoxomil and chlorthalidone oral tablets. Takeda Pharmaceuticals America, Inc (Per Manufacturer), Deerfield, IL, 2011
- 2. Edarbi oral tablets, azilsartan medoxomil oral tablets. Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2011
- 3. TEKTURNA(R) oral tablets, pellets, aliskiren oral tablets, pellets. Noden Pharma USA Inc (per FDA), Boston, MA, 2017.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	9/2010
2	Update	Moved to updated template Updated age restrictions	All	2/2020
3	Update	Updated age restrictions to match FDA label Removed candesartan/HCT and	All	1/1/2021
		Olmesartan/HCT from Step 1 agents Added		
		telmisartan/HCT,telmisartan/amlod ipine, candesartan/HCT, eprosartan, candesartan, olmesartan, olmesartan/HCT, amlodipine/olmesartan, aliskiren, amlodipine/valsartan, telmisartan to Step 2 agents		
4	Update Policy	Added Valsartan oral solution, updated age restriction on candesartan 1 to < 17 years old	Products affected, age restrictions	6/23/2022

## Policy Revision history



